FDA approval of dapagliflozin generic formulations; regulatory action does not evaluate clinical efficacy or comparative benefit.
Reported
Approval status date2026-04-06
Strengths approved5 mg, 10 mg
Loading
Company
1 development in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of dapagliflozin generic formulations; regulatory action does not evaluate clinical efficacy or comparative benefit.